

IJAPC

VOLUME 9 ISSUE 3 2018

GREENTREE GROUP PUBLISHERS

E ISSN 2350-0204

WWW.IJAPC.COM

"A peer-reviewed journal dedicated to allied Sciences"



Int J Ayu Pharm Chem

REVIEW ARTICLE

www.ijapc.com

e-ISSN 2350-0204

A Conceptual Study of Understanding the Effects of Phthalates on Human Health and its Management with special reference To *Dooshi Visha* (Cumulative Toxicity)

Vijay Javagal^{1*}, Prakash L Hegde² and Keerthana J³

¹⁻³Department of Dravyaguna, Sri Dharmastala Manjunatheshwara College of Ayurveda, Thaneerhalla, Hassan, Karnataka, India

ABSTRACT

Human beings are invariably accustomed to the usage of plastics. These plastics pose various health hazards on the human population. According to the Global Industry Analysts in the year 2015, 297.5million tons of plastic were used. To increase the durability and elasticity of the plastic various plasticizers are being used. The utmost common plasticizer used is Phthalates. Phthalates are the di esters of 1, 2 – benzenedicarboxylic acid (phthalic acid). Phthalates have got various health hazards. Phthalates are nanoparticles and they surpass the placenta, breast milk, enterohepatic circulation leading to various systemic illness and complications pertaining to the same. Hence it is imperative to prevent the usage of Phthalates and also detoxification of the same has to be done based on classics. Pertaining to the classical reference it is clear that the Phthalates can be reflected to be similar with the theory of *Dooshi visha (cumulative toxicity)* as per *Ayurveda*; indulgence of the same will lead to various health hazards and complications. This paper aims to review the effect of Phthalates on human health and its management w. s. r. to *Dooshi visha (cumulative toxicity)*. Based on the treatment notion of *Dooshi Visha* i.e various *Panchakarma* modalities one can reduce the complications as well as move towards *Swasthya*.

KEYWORDS

Phthalates, plasticizers, detoxification, Dooshi visha (cumulative toxicity), Nidana Parivarjana, swasthya



Received 16/08/18 Accepted 14/09/18 Published 10/11/18



INTRODUCTION

Phthalates are the most commonly used plasticizers; they are a cluster of manmade chemicals termed as diesters of 1, 2benzenedicarbolic acid (phthalic acid). Phthalates are basically divided into high molecular weight Phthalates for e.g. di (2ethylexyl) phthalate [DEHP], di-isononyl phthalate [DiNP], di-n-octyl phthalate [DnOP] and low molecular weight Phthalates for e.g. diethyl phthalate [DEP] dibutyl phthalate [DBP]. High and molecular weight Phthalates (Flexible vinyl) is used in the production of consumer food contact applications, products, floorboards and wall covering, and medical devices¹⁻³. Low molecular Phthalates are utilised in the production of personal care products, and in making polishes, as thinners and plasticizers for cellulose acetate, polishes, and coverings, including those used to provide programed releases in some pharmaceuticals³⁻⁵. Phthalates have a extensive range of applicability in consumer products and personal care hence has a high risk of non-occupational human exposure, which in turn causes various health hazards such as developmental anomalies, male reproductive health, female reproductive health, pregnancy outcome and respiratory health⁶. In Ayurveda, interpretation of Phthalates can

be done under the theory of Dooshi visha (cumulative toxicity). Dooshi visha (cumulative toxicity) is a part of Sthawara, Jangama or Krutrimvisha, which cannot be banished from the body but instead becomes less persuasive after digestion or the counter action of antidotes (*Prativisha*) stays in the body for an extended period and vitiating it slowly⁷. Favorable conditions can create a variety of symptoms in a patient affected by Dooshivisha. The manifestations may be very wide from Jwara to Kushta and Unmada, hence one has to give more importance in prevention and management of *Dooshi* visha $(cumulative\ toxicity)^8$.

OBJECTIVES

- 1. To collect and analyse the literature of Phthalates and human health.
- 2. To collect and analyse the literature review of *Dooshi visha* (*cumulative toxicity*).
- 3. To compare the symptoms of *Dooshi visha* (*cumulative toxicity*) with Phthalates.
- 4. To analyse the management principles based on the classical literature.

To fulfil the aims and objectives of this study, work has been undertaken in the following phase wise manner.

- 1. Conceptual study
- 2. Discussion
- 3. Conclusion



CONCEPTUAL STUDY

Phthalates and Human Health

Phthalates have an inclusive range of utility in consumer products and personal care hence non-occupational human exposure of Phthalates is high. However, route of acquaintance to Phthalates is unknown. Conventionally, ingestion has considered an imperative route of exposure. Due to low volatility Phthalates are present in housing indoor air⁹⁻¹⁰. Dermal contact and parenteral acquaintance from medical devices containing Phthalates may also add to exposure²⁻¹¹. On exposure, Phthalates are swiftly processed and excreted in urine and faeces¹⁻⁵. The fraction of free monoester excretion in humans differs depending on the aqueous solubility of the phthalate metabolites¹²⁻¹³.

Internal Dose of Phthalates

Phthalates are extensively used in laboratory and medical products and therefore sample contamination is difficult to avoid. Human studies using the phthalate diesters as biomarkers of exposure were limited to highly exposed populations. A diverse method uses urinary phthalate monoester metabolites as biomarkers of exposure¹⁴⁻¹⁹. Chromatography coupled with mass spectrometric techniques can be used to measure Phthalate monoesters in biological matrices, of which most common

is high performance liquid chromatography (HPLC). Phthalate monoesters after conversion to volatile derivatives can be measured by using Gas chromatography ²⁰.

Effects on Human Health

An assessment of data emerging from in silico, in vitro and in vivo approaches on Phthalates would provide various hazardous impacts on humans²¹. The most important contrary effects of Phthalates are seen in foetal development, endocrine and reproductive anomalies, especially the so-called "phthalate syndrome"²² which are further discussed in Table-1.

These are the adverse health effects impacted by Phthalates on humans²²

- ➤ Phthalates vs. Endocrine disrupting chemicals, the EDCs
- ➤ Allergy & Asthma
- > Phthalates and child health
- > Phthalates and women health
- Phthalates and Men health
- ➤ Phthalates Vs Overweight and Obesity
- ➤ Phthalates Vs Cancer

Concept of Dooshi visha (cumulative toxicity)

The term *Dooshivisha* is a compound of two different words, '*Dooshi*' and '*Visha*'. '*Dooshi*' means denatured, tempered, reformed, dormant, vitiated or something which influences the system in the long run. '*Visha*' means poison²⁴. Poison which is



devoid of the ten innate properties of *Visha* and unable to produce any acute symptoms of poisoning can also be termed as *Dooshivisha*. *Dooshivisha* is *Avibhavyamana* i. e the one which is not

traceable due to *Avarana by Kapha Dosha*. Due to its ability to remain in the system for prolonged periods of time it is termed *Varshagananubandhi*²⁵.

Table 1 Effects of Phthalates on Human health²³

Phthalate diester	Possible sources of exposure	Possible health effects
Diethyl phthalate	Personal-care products (e.g. fragrances), dyes, insecticides, coatings (e.g. pharmaceuticals)	Reduced growth rate, food consumption and increased organ weights
Di-n-butyl phthalate	Cellulose acetate plastics, personal care products (e.g. nail polish, cosmetics), lacquers, varnishes, coatings (e.g. pharmaceuticals)	Renal and hepatic effects, developmental effect and reproductive effects, cryptorchidism, reduced foetal weight, hypospadias, reduction in anogenital distance in males.
Butylbenzyl phthalate	Vinyl floorboards, glues and sealants, car- care merchandises, industrial solvents, toys, food wrapping, synthetic leather, personal- care products	Testicular toxicity, cryptorchidism, teratogenic, modulates steroid hormone levels, reduced anogenital distance
Di(2- ethylhexyl) phthalate	PVC plastics used in domestic products (e.g. toys, flooring and furniture, wall coverings), food wrapping, blood storage bags and medical devices	Hepatocellular carcinoma, testicular toxicity, teratogenic at high doses, anovulation, affects fetal growth

Clinical features of *Dooshivisha*²⁶

Intoxication, fainting and discoloration, intermittent fever, oligospermia, urticaria, vomiting, epileptic attacks, increased thirst, Appearance of red patches throughout the body, indigestion, diarrhoea, insanity, distension of the abdomen, Oedema of the face and extremities, Skin disorders.

Complications of *Dooshivisha*²⁷

Pyrexia, Diarrhea, Burning sensation, Fainting, Hiccough, Cardiac disorders, Distension of abdomen, Abdominal enlargement, Oligospermia, Insanity, Oedema, Tremors.

Transformation of Visha into Dooshivisha²⁸

1. Jeernam Visham (Partly **metabolized**): It has got two aspects (A) When Visha, which is proficient of producing acute ill effects, is kept for long time, some of them may lose their original properties, ultimately getting converted into less potent Visha, which is Dooshivisha. (B) Poison (Visha) whether inanimate (Sthaavara), animate (Jangama) artificial (Kritrima) which is not completely removed from the body or partly detoxified and being retained or amassed in the body and confined at various sites of tissues



producing cumulative effect is *Dooshivisha*.

- **2. Exposure to** *Davagni*: Exposure to heat flame or fire etc. converts *Visha* in to latent poison (*Dooshivisha*).
- **3.** Exposure to *Vata*: Cold wind desiccates the water content of Poison (*Visha*) thus transforming potent *Visha* in to less potent *Dooshivisha*.
- **4. Exposure to** *Aatapam*: *Vishadravyas* when exposed to sun detoxification occurs at the maximum rate, which in turn reduces the potency of poison.
- **5.** Naturally Less Potent (*Swabhavato Gunaviprahinam*): Presence of all 10 *Gunas in Visha* can cause acute or sub-acute poisoning. But if anyone or more of these properties (*Gunas*) are absent in a

particular *Visha*, it can become *Dooshivisha* that is of low potency by nature. Ingesting of these will produce symptoms of *Dooshivisha* which flares up in the presence of aggravating factors.

GENERAL PRINCIPLES IN THE MANAGEMENT OF DOOSHI VISHA (CUMULATIVE TOXICITY)²⁹⁻³²

The patient of *Dooshi visha* (cumulative toxicity) should be administered *Swedan* (sudation therapy) followed by *Vaman* (emesis) and *Virechana* (purgative therapies) as discussed in Table-2, tailed by *Dooshi vishari agada* (antidote) for internal administration with honey.

Table 2 Treatment principles

1	1	
Hetu Viprit Chikitsa	The treatment should be opposite to the nature of causative <i>Dosha</i>	
Vaman	One should take cold bath after <i>Vamana</i> , because poison is having hot potency	
	and it aggravates pitta Dosha so to pacify Pitta Dosha cold water bath is	
	indicated.	
Agadapana	Agada (anti poisonous medicine) should be administered mixed with Honey and	
	ghee immediately15.	
Kushtaghana and	For skin manifestation	
Rakthashodaka		
Aushadha		
Kapha Dosha	Vaman is indicated and application of paste of drugs (drug possess hot and	
Predominance	penetrating property). Foods should be pungent, astringent and bitter tastes.	
Pitta Dosha	ta Dosha Mild Virechana (purgations), Swedana (sudation), poultices applied very cold	
Predominance	and foods which are bitter, astringent and sweet in taste, added with ghee.	
Vata Dosha	Foods which is sweet, unctuous (fatty), sour, salty and added with ghee,	
Predominance	application of drugs of the same properties and of meat as food.	

DISCUSSION

As Phthalates are extensively used in consumer and personal care products non-

occupational exposure is unavoidable, hence leads to the various health hazards. Exposure to Phthalates and its health



hazards can be understood .under the notion of *Dooshi visha* (*cumulative toxicity*) based on the description in Table-3.

Table 3 *Dooshi visha* and Phthalates

Dooshi visha (cumulative toxicity)	Phthaltes	
Poison (Visha) whether inanimate (Sthaavara), animate	On exposure, Phthalates are quickly	
(Jangama) or artificial (Kritrima) which are partially	metabolised and expelled in faeces and urine.	
eliminated from the body or partly detoxified and being	Part of the Phthalates remnants in the body	
retained or collected in the body and localized at various	after phase 1 and 2biotransformation.	
sites of tissues producing cumulative effect is Dooshivisha.	Acquaintance to Phthalates is assessed by the	
	rate of excretion and health hazards are based	
	on the remnants of Phthalates in the body.	
Kritrima Visha (Artificial poison)	Artificial poison	
Similar clinical features and complications are seen as mentioned in conceptual study		
General principle of Ayurvedic management	No specific treatment, treatment based on	
	signs and symptoms	

Based on the above comparison we can clinch that Phthalates can be grouped under the notion of *Dooshi visha* (cumulative toxicity). As there are no specific line of treatment for Phthalates, treatment of *Dooshi visha* (cumulative toxicity) is applicable where the prime importance is given to *Nidana Parivarjana*.

CONCLUSION

The world is so vigilant about the impact of Phthalates on environment and human health. Currently it is one among the global threats. From above study, the *Lakshana* of *Dooshi visha* (*cumulative toxicity*) described in *BruhatrayiSamhita*, are near about similar to that of hazards of Phthalates exposure. The notion of *Dooshi visha* (*cumulative toxicity*) described in ancient times totally resembles in today's lifestyle, this shows how deeply our *Aacharyas* studied about *Visha* and their

properties. Based on which we can understand the effects of Phthalates on human health and its management under the notion of *Dooshi visha* (cumulative toxicity). Management is generally based on *Doshas* where *Shodhana* being the prime modality. It is alarming for us, to have sound knowledge of such silent poisoning, which is hazardous to our health.



REFERENCES

- 1. ATSDR. Toxicological profile for di-n-octyl phthalate (DNOP). Atlanta, GA: Agency for Toxic Substances and Disease Registry, 1997.
- 2. ATSDR. Toxicological profile for di(2-ethylhexyl)phthalate (DEHP). Atlanta, GA: Agency for Toxic Substances and Disease Registry, 2002.
- 3. David RM, McKee RH, Butala JH, et al. Esters of aromatic mono-, di-, and tricarboxylic acids, aromatic diacids, and di-, tri-, or polyalcohols. In: Bingham E, Cohrssen B, Powell CH, eds. Patty's toxicology. New York: John Wiley and Sons, 2001:635–932.
- 4. ATSDR. Toxicological profile for diethyl phthalate (DEP). Atlanta, GA: Agency for Toxic Substances and Disease Registry, 1995.
- 5. ATSDR. Toxicological profile for di-n-butyl phthalate (DBP). Atlanta, GA: Agency for Toxic Substances and Disease Registry, 2001.
- 6. Hauser, R. (2005). PHTHALATES AND HUMAN HEALTH. Occupational and Environmental Medicine, 62(11), 806-818. doi: 10.1136/oem.2004.017590.
- 7. Vaidya Yadavaji Trikamji Acharya editor Sushruta Samhita of Sushruta with the Nibandhasangraha commentary of Shri Dalhanacharya, Kalpasthana 2/25-26, Chaukhamba Surabharati Prakashan, Varanasi, 2012:565
- 8. Vaidya Yadavaji Trikamji Acharya editor Sushruta Samhita of Sushruta with the Nibandhasangraha commentary of Shri Dalhanacharya, Kalpasthana 2/33,

- Chaukhamba Surabharati Prakashan, Varanasi, 2012:566
- 9. Adibi JJ, Perera FP, Jedrychowski W, et al. Prenatal exposures to Phthalates among women in New York City and Krakow, Poland. Environ Health Perspect 2003; 111:1719–22. 10.Rudel R, Camann D, Spengler JD, et al. Household exposure to Phthalates, pesticides, alkylphenols, pbdes, and other endocrine active compounds Toxicol Sci 2003;72:184.
- 11.FDA. Safety assessment of di(2-ethylhexyl)phthalate (DEHP) released from PVC medical devices. Rockville, MD: Center for Devices and Radiological Health, US Food and Drug Administration, 2001.
- 12.Calafat AM, Silva MJ, Reidy JA, et al. Mono-(3-carboxypropyl) phthalate, a metabolite of di-n-octyl phthalate. J Toxicol Environ Health Part A. In press.
- 13.Kato K, Silva MJ, Reidy JA, et al. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Perspect 2004: 112:327–30.
- 14.Dirven HAAM, VandenBroek PHH, Jongeneelen FJ. Determination of 4 metabolites of the plasticizer di(2-ethylhexyl)phthalate in human urine samples. Int Arch Occup Environ Health 1993;64:555–60.
- 15. Ching NPH, Jham GN, Subbarayan C, et al. Gas chromatographic-mass spectrometric detection of circulating plasticizers in surgical patients. J Chromatogr 1981; 222:171–7.
- 16. Faouzi MA, Dine T, Gressier B, et al. Exposure of hemodialysis patients to di- 2-



ethylhexyl phthalate. Int J Pharm 1999; 180:113–21.

17.Mettang T, Thomas S, Kiefer T, et al. Uraemic pruritus and exposure to di(2-ethylhexyl)phthalate (DEHP) in haemodialysis patients. Nephrol Dial Transplant 1996; 11:2439–43.

18. Pollack GM, Buchanan JF, Slaughter RL, et al. Circulating concentrations of di(2-ethylhexyl) phthalate and its de-esterified phthalic-acid products following plasticizer exposure in patients receiving hemodialysis. Toxicol Appl Pharmacol 1985; 79:257–67.

19.Blount BC, Milgram KE, Silva MJ, et al. Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. Anal Chem 2000;72:4127–34.

20.Koch HM, Bolt HM, Angerer J. Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. Arch Toxicol 2004: 78:123–30.

21. Hauser and Calafat, 2005; Huang et al., 2009; Halden, 2010; Latini et al., 2010; Casals-Casas and Desvergne, 2011; Kim and Park 2014; Legler et al., 2015; Le Moal et al., 2015 22. Sailas Benjamin, Eiji Masai, Naofumi Kamimura, Robin Kenji Takahashi, Panichikkal C.Anderson. Abdul Faisal. Phthalates impact human health: Epidemiological evidences and plausible mechanism of action, Journal of Hazardous Materialshttp://dx.doi.org/10.1016/j.jhazmat.2 017.06.036

23.Hauser, R. (2005). PHTHALATES AND HUMAN HEALTH. Occupational and

Environmental Medicine, 62(11), 806-818. doi: 10.1136/oem.2004.017590.

24. Ayurvediya Sabdakosa (Sanskrti – Sanskrit): V.M. Joshi and N.H. Joshi, Maharashtra Rajya Sahitya Ani Sanskrit Mandal, Mumbai, 1968.

25.Pa.Hari Sadashiv Shastri Paradkar editor Ashtanga Hridaya of Vagbhata with the Sarvangsundara of Arundatta & Ayurvedarasayana of Hemadri, Uttarsthana 35/35-36, Chaukhamba Surabharati Prakashan, Varanasi, 2010:904-905

26. Vaidya Yadavaji Trikamji Acharya editor Sushruta Samhita of Sushruta with the Nibandhasangraha commentary of Shri Dalhanacharya, Kalpasthana 2/34-35, Chaukhamba Surabharati Prakashan, Varanasi, 2012:566

27. Vaidya Yadavaji Trikamji Acharya editor Sushruta Samhita of Sushruta with the Nibandhasangraha commentary of Shri Dalhanacharya, Kalpasthana 2/53, Chaukhamba Surabharati Prakashan, Varanasi, 2012:567

28. Vaidya Yadavaji Trikamji Acharya editor Sushruta Samhita of Sushruta with the Nibandhasangraha commentary of Shri Dalhanacharya, Kalpasthana 2/25-26, Chaukhamba Surabharati Prakashan, Varanasi, 2012:565

29. PV Sharma, charaka samhita, Chikitsasthana, (23/62), Edition, Chaukhamba Orientalia, Varanasi, 2008, 4.

30.Dr.Asha Kumari, Dr. Premvati Tewari, English commentary, Yogaratnakara, 1st



Edition Chaukhamba Visvabharati Varanasi, 2010.

31.Dr.Asha Kumari, Dr. Premvati Tewari, English commentary, Yogaratnakara, 1st Edition Chaukhamba Visvabharati Varanasi, 2010.

32.K.R.Srikanth Murthy, English commentary, Astanga Hrudaya, Uttara Sthana, (35/66)1st Edition, Krishnadas Academy Varansi, 1995, 3.